Synthesis and biological evaluation of neutral and zwitterionic 3-carboranyl thymidine analogues for boron neutron capture therapy

Journal of Medicinal Chemistry

Volumn 48, Issue 4, 2005, Pages 1188-1198

  Byun, Youngjoo ^a   Yan, Junhua ^a   Al Madhoun, Ashraf S ^b,c   Johnsamuel, Jayaseharan ^a   Yang, Weilian ^a   Barth, Rolf F ^a   Eriksson, Staffan ^b   Tjarks, Werner ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^c UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 (7 AMMONIUM 3 CARBORAN 1 YL)PROPAN 1 YL]THYMIDINE; 3 CARBORANYLTHYMIDINE DERIVATIVE; AMINE; AMMONIA; AMPHOLYTE; BORON; CARBORANE DERIVATIVE; THYMIDINE DERIVATIVE; THYMIDINE KINASE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN L 929; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME SUBSTRATE; MOLECULAR LIBRARY; MOUSE; NEUTRON CAPTURE THERAPY; NONHUMAN; PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; BIOLOGICAL AVAILABILITY; BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; CELL LINE, TUMOR; HUMANS; IONS; MICE; MICE, NUDE; PHOSPHORYLATION; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; THYMIDINE; THYMIDINE KINASE; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 13944281680     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0491896     Document Type: Article

References (51)

1. Soloway, A. H.; Tjarks, W.; Barnum, B. A.; Hong, F.-G.; Barth, R. F.; Codogni, I. M.; Wilson, J. G. The chemistry of neutron capture therapy. Chem. Rev. 1998, 98, 1515-1562.
2. Al-Madhoun, A. S.; Johnsamuel, J.; Yan, J.; Ji, W.; Wang, J.; Zhuo, J.-C.; Lunato, A. J.; Woollard, J. E.; Hawk, A. E.; Cosquer, G. Y.; Blue, T. E.; Eriksson, S.; Tjarks, W. Synthesis of a small library of 3-(carboranylalkyl) thymidines and their biological evaluation as substrates for human thymidine kinases 1 and 2. J. Med. Chem. 2002, 45, 4018-4028.
3. Byun, Y.; Van, J.; Al-Madhoun, A. S.; Johnsamuel, J.; Yang, W.; Earth, R. F.; Eriksson, S.; Tjarks, W. The synthesis and biochemical evaluation of thymidine analogues substituted with nido carborane at the N-3 position. Appl. Radiat. Isot. 2004, 61, 1125-1130.
4. Johnsamuel, J.; Lakhi, N.; Al-Madhoun, A. S.; Byun, Y.; Yan, J.; Eriksson, S.; Tjarks, W. Synthesis of ethyleneoxide modified 3-carboranyl thymidine analogues and evaluation of their biochemical, physicochemical, and structural properties. Bioorg. Med. Chem. 2004, 12, 4769-4781.
5. Lunato, A. J.; Wang, J.; Woollard, J. E.; Anisuzzaman, A. K. M.; Ji, W.; Rong, F.-G.; Ikeda, S.; Soloway, A. H.; Eriksson, S.; Ives, D. H.; Blue, T. E.; Tjarks, W. Synthesis of 5-(carboranylalkylmercapto)-2′-deoxyuridines and 3-(carboranylalkyl)thymidines and their evaluation as substrates for human thymidine kinases 1 and 2. J. Med. Chem. 1999, 42, 3378-3389.
6. Tjarks, W.; Anisuzzaman, A. K. M.; Liu, L.; Soloway, A. H.; Barth, R. F.; Perkins, D. J.; Adams, D. M. Synthesis and in vitro evaluation of boronated uridine and glucose derivatives for boron neutron capture therapy. J. Med. Chem. 1992, 35, 1628-1633.
7. Yan, J.; Naeslund, C.; Al-Madhoun, A. S.; Wang, J.; Ji, W.; Cosquer, G. Y.; Johnsamuel, J.; Sjoberg, S.; Eriksson, S.; Tjarks, W. Synthesis and biological evaluation of 3′-carboranyl thymidine analogues. Bioorg. Med. Chem. Lett. 2002, 12, 2209-2212.
8. Fulcrand-El Kattan, G.; Lesnikowski, Z. J.; Yao, S.; Tanious, F.; Wilson, W. D.; Schinazi, R. F. Carboranyl oligonucleotides. 2. Synthesis and physicochemical properties of dodecathymidylate containing 5-(o-carboran-1-yl)- 2′-deoxyuridine. J. Am. Chem. Soc. 1994, 116, 7494-7501.
9. Imamura, K.-i.; Yamamoto, Y. Synthesis and in vitro evaluation of 5-closo- and 5-nido-orthocarboranyluridines as boron carriers. Bull. Chem. Soc. Jpn. 1997, 70, 3103-3110.
10. Kabalka, G. W.; Reddy, N. K.; Narayana, C. Synthesis of boronated uridine derivatives for boron neutron capture therapy. Cancer Neutron Capture Therapy; Plenum Press: New York, 1996; pp 157-161.
11. Schinazi, R. F.; Prusoff, W. H. Synthesis of 5-(dihydroxyboryl)-2′- deoxyuridine and related boron-containing pyrimidines. J. Org. Chem. 1985, 50, 841-847.
12. Schinazi, R. F.; Hurwitz, S. J.; Liberman, I.; Juodawlkis, A. S.; Tharnish, P.; Shi, J.; Liotta, D. C.; Coderre, J. A.; Olson, J. Treatment of isografted 9L rat brain tumors with β-5-o-carboranyl-2β-deoxyuridine neutron capture therapy. Clin. Cancer Res. 2000, 6, 725-730.
13. Mourier, N.; Eleuteri, A.; Schinazi, R. F. Synthesis and biological evaluation of new enantiomers of 5-o-carboranyl pyrimidine nucleosides. Nucleosides Nucleotides 1999, 18, 575-576.
14. Lesnikowski, Z. J.; Shi, J.; Schinazi, R. F. Nucleic acids and nucleosides containing carboranes. J. Organomet. Chem. 1999, 581, 156-169.
15. Hurwitz, S. J.; Ma, L.; Eleuteri, A.; Wright, J.; Moravek, J.; Schinazi, R. F. Cellular pharmacology of the D- and L-enantiomers of β-5-o- carboranyl-2′-deoxyuridine. Nucleosides Nucleotides Nucleic Acids 2000, 19, 691-702.
16. Graciet, J.-C. G.; Shi, J.; Schinazi, R. F. Synthesis and biological properties of the four optical isomers of 5-o-carboranyl-2′,3′- didehydro-2′,3′-dideoxyuridine. Nucleosides Nucleotides 1998, 17, 711-727.
17. Goudgaon, N. M.; Fulcrand El-Kattan, G.; Schinazi, R. F. Boron containing pyrimidines, nucleosides, and oligonucleotides for neutron capture therapy. Nucleosides Nucleotides 1994, 13, 849-880.
18. Nemoto, H.; Cai, J.; Yamamoto, Y. Synthesis of a water-soluble o-carbaborane bearing a uracil moiety via a palladium-catalyzed reaction under essentially neutral conditions. J. Chem. Soc., Chem. Commun. 1994, 577-578.
19. Eriksson, S.; Munch-Petersen, B.; Johansson, K.; Eklund, H. Structure and function of cellular deoxyribonucleoside kinases. Cell. Mol. Life Sci. 2002, 59, 1327-1346.
20. Barth, R. F.; Yang, W.; Al-Madhoun, A. S.; Johnsamuel, J.; Byun, Y.; Chandra, S.; Smith, D. R.; Tjarks, W.; Eriksson, S. Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors. Cancer Res. 2004, 64, 6287-6295.
21. Al-Madhoun, A. S.; Johnsamuel, J.; Barth, R. F.; Tjarks, W.; Eriksson, S. Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy. Cancer Res. 2004, 64, 6280-6286.
22. Yamamoto, K.; Endo, Y. Utility of boron clusters for drug design. Hansch-Fujita hydrophobic parameters π of dicarba-closo-dodecaboranyl groups. Bioorg. Med. Chem. Lett. 2001, 11, 2389-2392.
23. Thirumamagal, B. T. S.; Johnsamuel, J.; Al-Madhoun, A. S.; Cosquer, G. Y.; Byun, Y.; Yan, J.; Barth, R. F.; Eriksson, S.; Tjarks, W. Boronated thymidine analogues for boron neutron capture therapy. Nucleosides Nucleotides Nucleic Acids 2004, submitted.
24. 11. J. Organomet. Chem. 2002, 657, 247-255.
25. Cass, E. C.; Young, J. D.; Baldwin, S. A. Recent advances in the molecular biology of nucleoside transporters of mammalian cells. Biochem. Cell Biol. 1998, 76, 761-770.
26. Cabrita, M. A.; Baldwin, S. A.; Young, J. D.; Cass, C. E. Molecular biology and regulation of nucleoside and nucleobase transporter proteins in eukaryotes and prokaryotes. Biochem. Cell Biol. 2002, 80, 623-638.
27. Baldwin, S. A.; Mackey, J. R.; Cass, C. E.; Young, J. D. Nucleoside transporters: Molecular biology and implications for therapeutic development. Mol. Med. Today. 1999, 5, 216-224.
28. Hansch, C.; Bjoerkroth, J. P.; Leo, A. Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J. Pharm. Sci. 1987, 76, 663-687.
29. Johansson, N. G.; Eriksson, S. Structure-activity relationships for phosphorylation of nucleoside analogues to monophosphates by nucleoside kinases. Acta Biochim. Pol. 1996, 43, 143-160.
30. Tjarks, W. The use of boron clusters in the rational design of boronated nucleosides for neutron capture therapy of cancer. J. Organomet. Chem. 2000, 614-615, 37-47.
31. Valliant, J. F.; Guenther, K. J.; King, A. S.; Morel, P.; Schaffer, P.; Sogbein, O. O.; Stephenson, K. A. The medicinal chemistry of carboranes. Coord. Chem. Rev. 2002, 232, 173-230.
32. Zakharkin, L. I.; Brattsev, V. A.; Chapovskii, Y. A. Some transformations of alkyl halides, alcohols, and acids of carborane series. Zh. Obshch. Khim. 1965, 35, 2160-2167.
33. Grafstein, D.; Bobinski, J.; Dvorak, J.; Smith, H. F.; Schwartz, N. N.; Cohen, M. S.; Fein, M. M. Carboranes. III. Reactions of the carboranes. Inorg. Chem. 1883, 2, 1120-1125.
34. Keying, T. L.; Ager, J. W., Jr.; Clark, S. L.; Alexander, R. P.; Papetti, S.; Reid, J. A.; Trotz, S. I. A new series of organoboranes. III. Some reactions of 1,2-dicarbaclovododecaborane(12) and its derivatives. Inorg. Chem. 1863, 2, 1097-1105.
35. Kasar, R. A.; Knudsen, G. M.; Kahl, S. B. Synthesis of 3-amino-1-carboxy-o-carborane and an improved, general method for the synthesis of all three C-amino-C-carboxycarboranes. Inorg. Chem. 1999, 38, 2936-2940.
36. Nelson, E. R.; Maienthal, M.; Lane, L. A.; Benderly, A. A. Synthesis of 2,2-dialkylcyclopropanenitrile. J. Am. Chem. Soc. 1957, 79, 3467-3469.
37. Martin, A. E.; Ford, T. M.; Bulkowski, J. E. Synthesis of selectively protected tri- and hexaamine macrocycles. J. Org. Chem. 1982, 47, 412-415.
38. Fox, M. A.; Wade, K. Deboronation of 9-substituted-ortho- and -meta-carboranes. J. Organomet. Chem. 1899, 573, 279-291.
39. Al-Madhoun, A. S.; Ji, W.; Johnsamuel, J.; Yan, J.; Lakhi, N.; Byun, Y.; Woollard, J.; Hawk, A.; Blue, T.; Tjarks, W.; Eriksson, S. The biological evaluation of a small library of 3-(carboranyl-alkyl) thymidines as substrates for human thymidine kinases 1 and 2. Research and Development in Neutron Capture Therapy; Modduzzi Press: Italy, 2002; pp 89-93.
40. Welin, M.; Kosinska, U.; Mikkelsen, N.-E.; Carnrot, C.; Zhu, C.; Wang, L.; Eriksson, S.; Munch-Petersen, B.; Eklund, H. Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 17970-17975.
41. Al-Madhoun, A. S.; Tjarks, W.; Eriksson, S. The role of thymidine kinases in the activation of pyrimidine nucleoside analogues. Mini-Rev. Med. Chem. 2004, 4, 341-350.
42. Busse, P. M.; Harling, O. K.; Palmer, M. R.; Kiger, W. S., III.; Kaplan, J.; Kaplan, I.; Chuang, C. F.; Goorley, J. T.; Riley, K. J.; Newton, T. H.; Santa Cruz, G. A.; Lu, X.-Q.; Zamenhof, R. G. A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease. J. Neurooncol. 2003, 62, 111-121.
43. Capala, J.; Stenstam Britta, H.; Skold, K.; af Rosenschold Per, M.; Giusti, V.; Persson, C.; Wallin, E.; Brun, A.; Franzen, L.; Carlsson, J.; Salford, L.; Ceberg, C.; Persson, B.; Pellettieri, L.; Henriksson, R. Boron neutron capture therapy for glioblastoma multiforme: Clinical studies in Sweden. J. Neurooncol. 2003, 62, 135-144.
44. 10B concentration predictions and dosimetric consequences. J. Neurooncol. 2003, 62, 171-186.
45. Kato, I.; Ono, K.; Sakurai, Y.; Ohmae, M.; Maruhashi, A.; Imahori, Y.; Kirihata, M.; Nakazawa, M.; Yura, Y. Effectiveness of BNCT for recurrent head and neck malignancies. Appl. Radiat. Isot. 2004, 61, 1069-1073.
46. Liberman, S. J.; Dagrosa, A.; Jimenez Rebagliati, R. A.; Bonomi, M. R.; Roth, B. M.; Turjanski, L.; Castiglia, S. I.; Gonzalez, S. J.; Menendez, P. R.; Cabrini, R.; Roberti, M. J.; Batistoni, D. A. Biodistribution studies of boronophenylalanine-fructose in melanoma and brain tumor patients in Argentina. Appl. Radiat. Isot. 2004, 61, 1095-1100.
47. Joensuu, H.; Kankaanranta, L.; Seppala, T.; Auterinen, I.; Kallio, M.; Kulvik, M.; Laakso, J.; Vahatalo, J.; Kortesniemi, M.; Kotiluoto, P.; Seren, T.; Karila, J.; Brander, A.; Jarviluoma, E.; Ryynanen, P.; Paetau, A. et al. Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine. J. Neurooncol. 2003, 62, 123-134.
48. Tjarks, W.; Wang, J.; Chandra, S.; Ji, W.; Zhuo, J.; Lunato, A. J.; Boyer, C.; Li, Q.; Usova, E. V.; Eriksson, S.; Morrison, G. H.; Cosquer, G. Y. Synthesis and biological evaluation of boronated nucleosides for boron neutron capture therapy (BNCT) of cancer. Nucleosides Nucleotides Nucleic Acids 2001, 20, 695-698.
49. Tjarks, W.; Wang, J.; Chandra, S.; Ji, W.; Zhuo, J. C.; Lunato, A. J.; Cosqur, G. Y.; Eriksson, S.; Morrison, G. H.; Spielvogel, B. F. Boronated nucleosides for BNCT. KURRI-TR. 2000, 157-158.
50. Dupertuis, Y. M.; Vasquez, M.; Mach, J.-P.; De Tribolet, N.; Pichard, C.; Slosman, D. O.; Buchegger, F. Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine. Cancer Res. 2001, 61, 7971-7977.
51. Barth, R. F.; Adams, D. M.; Soloway, A. H.; Mechetner, E. B.; Alam, F.; Anisuzzaman, A. K. M. Determination of boron in tissues and cells using direct-current plasma atomic emission spectroscopy. Anal. Chem. 1991, 63, 890-893.